Title: BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Principal Investigator: Jan A. Burger, MD, University of Texas MD Anderson Cancer Center
Description: This phase 2 trial is seeking to determine how the combination of zanubrutinib and rituximab work in the treatment of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma. The researchers hypothesize that zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The primary objective of the trial is to determine how many patients achieve treatment-free remission 6 months after the discontinuation of zanubrutinib. Secondary trial objectives include the determination of clinical factors that lead to treatment-free remission, treatment-free remission length, and the evaluation of efficacy of retreatment with the same combination in patients who relapse.
This study is sponsored by the University of Texas MD Anderson Cancer Center.
Clinicaltrials.gov. Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. NCT04458610. Accessed April 23, 2021.